Weight Loss Drugs Are Reducing Obesity Rates in the U.S., Survey Finds

The U.S. obesity rate has shown a notable decline, driven by the growing use of injectable weight loss medications, according to a new survey by Gallup’s National Health and Well-Being Index. The findings, which suggest a promising trend in the fight against obesity, indicate that new weight loss treatments are making a significant impact, though access to these medications remains a critical issue.

In 2023, the obesity rate among U.S. adults fell to 37%, a decline from 39.9% recorded just three years ago. This drop, while gradual, marks a shift in the country’s long-standing struggle with obesity, a condition that has worsened despite numerous public health initiatives and diet trends over the years.

The Surge in GLP-1 Weight Loss Drugs

The survey highlights that the use of injectable medications like semaglutide—branded as Ozempic and Wegovy—and tirzepatide—branded as Zepbound and Mounjaro—has more than doubled over the past 18 months. These drugs, part of a new class of treatments known as GLP-1 agonists, act by influencing hormones and brain signals to suppress appetite and slow digestion, making it easier for users to lose weight.

As of the latest survey, 12.4% of Americans report using these drugs for weight loss, a sharp increase from 5.8% just a year and a half ago when Gallup first measured their usage. These medications were first approved for weight loss in the U.S. in 2021, and they have since been lauded as a groundbreaking approach to tackling obesity and its related diseases, which have remained a persistent public health challenge.

Demographic Shifts and Gender Disparities

The survey results suggest that the most significant drops in obesity rates have occurred among adults aged 40 to 64, who have shown an increased reliance on GLP-1 medications. In this age group, the obesity rate dropped by 5 percentage points to 42.8%. Additionally, the data reveals that women are more likely to use these drugs compared to men, and they also appear to experience greater weight loss as a result.

For example, individuals aged 50 to 64, who make up the highest user group for these medications, have seen the most noticeable changes. While this age group represents a smaller proportion of the general population, their reliance on GLP-1 medications could be a significant factor in reducing national obesity trends in the coming years.

Challenges with Access and Cost

While the effectiveness of GLP-1 weight loss drugs is undeniable, the issue of access remains a critical hurdle. Dr. Fatima Cody Stanford, an obesity specialist at Harvard University, notes that many private insurers have already begun to scale back coverage for these medications. Starting next year, many health plans, including those that cover most of Dr. Stanford’s patients, will no longer offer coverage for GLP-1 drugs, which could make them unaffordable for a large segment of the population.

Without insurance coverage, patients could be required to pay up to $500 a month out-of-pocket for these injections. Though drugmakers are working on developing more affordable pill versions of the treatments, Dr. Stanford cautions that the costs may still prevent many people from accessing these potentially life-changing drugs.

“While the correlation between drug use and lower obesity rates is clear, access will become an even bigger issue moving forward,” she says. “For many people, the cost will simply be too high without adequate insurance coverage.”

A Turning Point in Obesity Treatment

Despite the challenges, the survey results indicate that the introduction of GLP-1 drugs marks a turning point in the U.S. obesity epidemic. Over the past few decades, various dietary trends, public health initiatives, and treatments have been tried, yet the obesity rate continued to climb. With the arrival of GLP-1 medications, however, there is hope that the country may be on the verge of reversing its obesity crisis, particularly for those who are most at risk.

As more people turn to these medications, the country could see continued improvements in public health, though much will depend on how quickly healthcare systems can adapt to ensure equitable access to these therapies.

For now, experts like Dr. Stanford remain cautiously optimistic but emphasize that widespread access to weight loss treatments, including GLP-1 drugs, will be essential to sustaining these promising trends.